猪脑心肌炎病毒样颗粒的免疫原性和安全性研究。

Immunogenicity and safety of virus-like particle of the porcine encephalomyocarditis virus in pig.

机构信息

National Veterinary Research and Quarantine Service, Anyang, Gyeonggi-do, 430-824, Republic of Korea.

出版信息

Virol J. 2011 Apr 15;8:170. doi: 10.1186/1743-422X-8-170.

BACKGROUND

In this study, porcine encephalomyocarditis virus (EMCV) virus-like particles (VLPs) were generated using a baculovirus expression system and were tested for immunogenicity and protective efficacy in vivo.

RESULTS

VLPs were successfully generated from Sf9 cells infected with recombinant baculovirus and were confirmed to be approximately 30-40 nm by transmission electron microscopy (TEM). Immunization of mice with 0.5 μg crude protein containing the VLPs resulted in significant protection from EMCV infection (90%). In swine, increased neutralizing antibody titers were observed following twice immunization with 2.0 μg crude protein containing VLPs. In addition, high levels of neutralizing antibodies (from 64 to 512 fold) were maintained during a test period following the second immunization. No severe injection site reactions were observed after immunization and all swine were healthy during the immunization period.

CONCLUSION

Recombinant EMCV VLPs could represent a new vaccine candidate to protect against EMCV infection in pig farms.

背景

本研究采用杆状病毒表达系统生成猪脑心肌炎病毒（EMCV）病毒样颗粒（VLPs），并在体内检测其免疫原性和保护效力。

结果

重组杆状病毒感染 Sf9 细胞后成功生成 VLPs，电镜（TEM）证实其直径约为 30-40nm。用含有 VLPs 的 0.5μg 粗蛋白免疫小鼠可显著抵抗 EMCV 感染（90%）。在猪中，两次免疫含有 2.0μg VLPs 的粗蛋白可引起中和抗体滴度显著增加。此外，第二次免疫后，中和抗体水平（64 至 512 倍）在检测期间保持较高水平。免疫后无严重的注射部位反应，免疫期间所有猪均健康。